Skip to main content

News

West Midlands-led trial finds continuous positive airway pressure (CPAP) reduces need for invasive ventilation in hospitalised COVID-19 patients

Published on 23/08/2021

Results from the RECOVERY-RS trial, which assessed different ways to provide oxygen support for patients in hospital with COVID-19, have found that continuous positive airway pressure (CPAP) reduced the need for invasive mechanical ventilation.

UHB recruited more than 400 patients to the trial – more than one third of the overall total. 

The trial compared the use of CPAP (oxygen and positive pressure delivered via a tightly fitting mask), with High Flow Nasal Oxygen (high pressure oxygen delivered up the nose) and standard care (standard oxygen therapy).

All three interventions are commonly used to treat COVID-19 patients before they are moved onto invasive ventilation in a critical care bed, but it was not known which, if any, resulted in better outcomes.

Preliminary data from the trial also suggest that the routine use of high flow nasal oxygenation (HFNO), which can consume large amounts of oxygen, should be reconsidered as it did not improve outcomes for COVID-19 patients compared with conventional oxygen therapy.

Based on the trial results, one person would avoid needing invasive ventilation within intensive care units (ICU) for every 12 people treated with CPAP instead of standard oxygen therapy.

Professor Gavin Perkins, Chief Investigator, UHB Consultant in Intensive Care and Professor in Critical Care Medicine at Warwick Medical School at the University of Warwick said: “The RECOVERY-RS trial showed that CPAP was effective at reducing the need for invasive ventilation, thus reducing pressures on critical care beds.

“By giving patients the most effective treatment to begin with, we can help prevent resource shortages in our NHS and make sure the right type of ventilation is available to patients when it is required.

“This is the first large trial of different types of ventilation in COVID-19. While it is encouraging that these results can help reduce the number of people who require invasive ventilation, it is important to stress that, where it is needed, invasive ventilation can be lifesaving.”

More news

Lung model

Birmingham leads the way in ground-breaking work for more effective lung disease treatment

UHB partners with medical technology company, Qureight, to build more diverse artificial intelligence models that accurately reflect communities.

New £30M research injection to improve treatment of inflammatory diseases

£30M research injection to improve treatment of inflammatory diseases

Increased funding for NIHR Birmingham Biomedical Research Centre will continue major medical science developments.

Preventative COVID-19 treatment to be trialled in Birmingham

A drug trial that could help to prevent the most vulnerable people from catching COVID-19 has begun today.

Read more news